Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major

Haematologica. 2018 Feb;103(2):e46-e49. doi: 10.3324/haematol.2017.181511. Epub 2017 Nov 2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Blood Transfusion
  • Janus Kinase 2 / antagonists & inhibitors*
  • Mice
  • Protein Kinase Inhibitors / therapeutic use*
  • Splenomegaly / drug therapy*
  • Splenomegaly / prevention & control
  • beta-Thalassemia / pathology*

Substances

  • Protein Kinase Inhibitors
  • Jak2 protein, mouse
  • Janus Kinase 2